特应性皮炎的新型靶向治疗药物研究进展

Update on Targeted Therapeutic for Atopic Dermatitis

特应性皮炎(AD)是慢性、复发性、炎症性皮肤病,常伴明显瘙痒,严重影响患者生活质量。传统的治疗药物往往存在许多局限性,且对中重度AD患者疗效不佳。近年来AD的新型靶向治疗药物对其目标分子具有较高的特异性,从而减少了具有广泛生物学作用的免疫抑制剂非靶点效应所引起的不良副作用。本文将对近年来用于治疗特应性皮炎的小分子拮抗剂、生物制剂、其他新型靶向治疗药物以及其相关靶点研究进展进行综述。

Atopic dermatitis(AD) is a kind of chronic,recurrent,inflammatory skin disease,which often associated with intense itching,and seriously impacts on quality of patients′ life.The efficacy of traditional therapies on moderate and severe AD is not ideal. In recent years,the novel targeted drugs for AD have a high specificity to their target molecules and less side effects.This article will review the recent researches of small molecular antagonists,biological agents,other novel targeted therapeutic and related targets in the treatment of atopic dermatitis.